Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study.

ABSTRACT:

Background

Country-specific data on outcomes of treatment with recombinant human growth hormone are lacking. We present such data for children treated with growth hormone in Canada.

Methods

We describe characteristics and outcomes of 850 children (mean age at baseline 8.5 yr) treated with growth hormone constituting the Canadian cohort of the multinational phase IV prospective observational Genetics and Neuroendocrinology of Short-stature International Study (GeNeSIS). The diagnosis associated with short stature was as determined by the investigator. Auxological data were evaluated yearly until near-adult height. Adverse events were assessed in all growth-hormone-treated patients.

Results

The diagnosis ascribed as the cause of short stature was growth hormone deficien

SUBMITTER: Deal C 

PROVIDER: S-EPMC6182101 | biostudies-literature | 2018 Jul-Sep

REPOSITORIES: biostudies-literature